Clinical Trials Browser

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

120 enrolled

Breast

HER2+ Breast Cancer

NCT04334330 2022-05-02

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Phase 2 Unknown

34 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

300 enrolled

Tumor-Agnostic

Neoplasms

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

18 enrolled

Breast

Breast Neoplasms

NCT03633331 2021-10-15

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Unknown

93 enrolled 8 charts

Breast

Estrogen Receptor-positive Breast Cancer

NCT05076695 2021-10-13

NeoTPPF

Phase 2 Unknown

37 enrolled

Breast

Estrogen Receptor-positive Breast Cancer

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Phase 3 Unknown

420 enrolled

Breast

Breast Neoplasms

NCT04858997 2021-07-15

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

Phase 2 Unknown

150 enrolled

Breast

Breast Neoplasms

NCT04856371 2021-04-23

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Phase 1 Unknown

228 enrolled

Breast

Advanced Breast Cancer

NCT04247633 2020-04-20

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Phase 2 Unknown

578 enrolled

Breast

Breast Neoplasms

NCT04318223 2020-03-23

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Phase 2 Unknown

168 enrolled

Breast

Breast Neoplasms

NCT01522989 2020-03-04

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

Phase 1 Unknown

37 enrolled

Tumor-Agnostic

Neoplasms

NCT02690480 2020-02-05

FLIPPER

Phase 2 Unknown

189 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02592746 2019-04-08

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Phase 2 Unknown

182 enrolled

Breast

Breast Neoplasms

NCT03756090 2018-12-07

PECP

Phase NA Unknown

100 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT03560856 2018-06-18

PALPETBIO

Phase 2 Unknown

54 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03454919 2018-03-06

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

Phase 2 Unknown

60 enrolled

Dermatologic

Melanoma

NCT03219554 2017-08-02

A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

Phase 2 Unknown

33 enrolled

Thymus Neoplasms

NCT02202200 2016-04-18

OPTIMUM

Phase 1/2 Unknown

40 enrolled

Dermatologic

Melanoma

NCT01709370 2013-12-31

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

Phase 2 Unknown

45 enrolled

Breast

ER Positive, HER2 Negative Breast Cancer

Clinical Trials

PalboSarc

CELEBRATE

OPTI-DOSE

UPSTREAM

CAT_PB

ROME

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NeoTPPF

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

FLIPPER

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

PECP

PALPETBIO

Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

OPTIMUM

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women